Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: ICAD

Market Cap 106M 91.79M 84.44M 79.42M 149M 9.98B 151M 1B 389M 4.9B 396M 388M 16.96B P/E 2023
-9.35x
P/E 2024 -8.59x
Enterprise Value 88.75M 77.14M 70.97M 66.75M 125M 8.39B 127M 844M 327M 4.12B 333M 326M 14.25B EV / Sales 2023
1.47x
EV / Sales 2024 1.6x
Free-Float
99.32%
Yield 2023 *
-
Yield 2024 -
1 year 3.58
Extreme 3.58
3.99
3 years 1.18
Extreme 1.18
4.02
5 years 1.05
Extreme 1.05
18.83
10 years 1.05
Extreme 1.05
21.44
Manager TitleAgeSince
Chief Executive Officer 61 10/03/2023
Director of Finance/CFO 54 17/07/2025
Corporate Secretary - 17/07/2025
Date Insider Type Main position Quantity % Market Cap.
17/07/25Issuer sale

Chief Executive Officer

519,350 1.9569%
17/07/25Issuer sale

Chief Financial Officer

158,488 0.5972%
17/07/25Issuer sale

Director

87,408 0.3293%
Change 5-day change 1-year change 3-year change Capi.($)
+3.75%-.--%+1.04%+230.77% 106M
-2.31%-6.55%+13.98%-14.07% 176B
-3.57%-5.73%-22.51%+22.11% 148B
-1.98%-5.65%-11.61%-26.48% 128B
-4.20%-8.19%-55.71%-17.25% 69.74B
-2.14%-0.98%+15.85%-5.72% 51B
-1.84%-1.25%-24.74%-34.38% 45.7B
-3.12%-8.23%+4.46%+2.64% 36.25B
-0.98%-3.81%+2.64%+32.62% 35.4B
-3.29%-7.36%-16.07%-22.25% 28.76B
Average +0.36%-2.50%-9.27%+16.80% 71.87B
Weighted average by Cap. +0.79%-3.05%-9.43%-7.01%

Financials

2023 2024
Net sales 17.32M 15.05M 13.85M 13.02M 24.4M 1.64B 24.69M 165M 63.85M 804M 64.99M 63.6M 2.78B 19.61M 17.04M 15.68M 14.75M 27.63M 1.85B 27.95M 186M 72.29M 910M 73.59M 72.01M 3.15B
Net income -4.85M -4.21M -3.88M -3.65M -6.83M -458M -6.91M -46.09M -17.87M -225M -18.19M -17.8M -778M -5.62M -4.88M -4.49M -4.22M -7.91M -531M -8.01M -53.4M -20.71M -261M -21.08M -20.63M -902M
Net Debt -21.21M -18.44M -16.96M -15.95M -29.89M -2B -30.23M -202M -78.19M -985M -79.6M -77.89M -3.41B -16.84M -14.64M -13.47M -12.67M -23.74M -1.59B -24.01M -160M -62.1M -782M -63.21M -61.86M -2.71B
Logo ICAD
iCAD Inc is a United States‑based company. The Company develops artificial intelligence solutions designed to support healthcare providers in the detection and diagnosis of cancer. The company focuses on providing clinically proven AI technologies that assist medical professionals in identifying cancer earlier, improving diagnostic accuracy, and enhancing workflow efficiency. Its solutions include platforms for cancer detection, breast density assessment, and risk evaluation, enabling clinicians to analyze medical images and support patient care decisions. The company leverages advanced data, clinical evidence, and AI‑driven technologies to deliver tools that integrate into existing healthcare systems and assist in screening and diagnostic processes across global markets.
Employees
66
  1. Stock Market
  2. Stocks
  3. ICAD Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!